1. Evaluation of the Pharmacokinetic Interaction Between the β3‐Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects. Issue 3 (14th May 2013) Authors: Krauwinkel, Walter J. J.; Kerbusch, Virginie M. M.; Meijer, John; Tretter, Reiner; Strabach, Gregory; Van Gelderen, E. Marcel Journal: Clinical pharmacology in drug development Issue: Volume 2:Issue 3(2013:Jul.) Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P‐glycoprotein. Issue 3 (3rd March 2014) Authors: Groenendaal, Dorien; Strabach, Gregory; Garcia‐Hernandez, Alberto; Kadokura, Takeshi; Heeringa, Marten; Mol, Roelof; Eltink, Charlotte; Onkels, Hartmut Journal: Clinical pharmacology in drug development Issue: Volume 3:Issue 3(2014:May/Jun.) Page Start: 194 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P‐glycoprotein and CYP3A4. (10th January 2013) Authors: Groenendaal, Dorien; Strabach, Gregory; Garcia‐Hernandez, Alberto; Kadokura, Takeshi; Heeringa, Marten; Mol, Roelof; Eltink, Charlotte; Onkels, Hartmut Journal: British journal of clinical pharmacology Issue: Volume 75:Number 2(2013:Feb.) Page Start: 440 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗